213 related articles for article (PubMed ID: 28400260)
41. Lack of Ovarian Secretions Reverts the Anabolic Action of Olanzapine in Female Rats.
Skrede S; González-García I; Martins L; Berge RK; Nogueiras R; Tena-Sempere M; Mellgren G; Steen VM; López M; Fernø J
Int J Neuropsychopharmacol; 2017 Dec; 20(12):1005-1012. PubMed ID: 29020342
[TBL] [Abstract][Full Text] [Related]
42. Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin.
Liu X; Feng X; Deng C; Liu L; Zeng Y; Hu CH
BMC Pharmacol Toxicol; 2020 Jun; 21(1):48. PubMed ID: 32605639
[TBL] [Abstract][Full Text] [Related]
43. Olanzapine Induced Dysmetabolic Changes Involving Tissue Chromium Mobilization in Female Rats.
Yang CP; Wang YY; Lin SY; Hong YJ; Liao KY; Hsieh SK; Pan PH; Chen CJ; Chen WY
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717287
[TBL] [Abstract][Full Text] [Related]
44. Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model.
Hahn MK; Chintoh A; Remington G; Teo C; Mann S; Arenovich T; Fletcher P; Lam L; Nobrega J; Guenette M; Cohn T; Giacca A
Eur Neuropsychopharmacol; 2014 Mar; 24(3):448-58. PubMed ID: 24001874
[TBL] [Abstract][Full Text] [Related]
45. Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution.
van der Zwaal EM; Luijendijk MC; Adan RA; la Fleur SE
Eur J Pharmacol; 2008 May; 585(1):130-6. PubMed ID: 18378227
[TBL] [Abstract][Full Text] [Related]
46. Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats.
Boyda HN; Ramos-Miguel A; Procyshyn RM; Töpfer E; Lant N; Choy HH; Wong R; Li L; Pang CC; Honer WG; Barr AM
Int J Neuropsychopharmacol; 2014 Jan; 17(1):77-90. PubMed ID: 23953063
[TBL] [Abstract][Full Text] [Related]
47. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration.
Chintoh AF; Mann SW; Lam L; Lam C; Cohn TA; Fletcher PJ; Nobrega JN; Giacca A; Remington G
J Clin Psychopharmacol; 2008 Oct; 28(5):494-9. PubMed ID: 18794643
[TBL] [Abstract][Full Text] [Related]
48. Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents.
Albaugh VL; Vary TC; Ilkayeva O; Wenner BR; Maresca KP; Joyal JL; Breazeale S; Elich TD; Lang CH; Lynch CJ
Schizophr Bull; 2012 Jan; 38(1):153-66. PubMed ID: 20494946
[TBL] [Abstract][Full Text] [Related]
49. Atypical Antipsychotic Drug Olanzapine Deregulates Hepatic Lipid Metabolism and Aortic Inflammation and Aggravates Atherosclerosis.
Chen CH; Shyue SK; Hsu CP; Lee TS
Cell Physiol Biochem; 2018; 50(4):1216-1229. PubMed ID: 30355932
[TBL] [Abstract][Full Text] [Related]
50. Additive effects of olanzapine and melanin-concentrating hormone agonism on energy balance.
Guesdon B; Denis RG; Richard D
Behav Brain Res; 2010 Feb; 207(1):14-20. PubMed ID: 19788900
[TBL] [Abstract][Full Text] [Related]
51. One-Year Treatment with Olanzapine Depot in Female Rats: Metabolic Effects.
Ersland KM; Myrmel LS; Fjære E; Berge RK; Madsen L; Steen VM; Skrede S
Int J Neuropsychopharmacol; 2019 May; 22(5):358-369. PubMed ID: 30854556
[TBL] [Abstract][Full Text] [Related]
52. Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways.
Lian J; Huang XF; Pai N; Deng C
Psychoneuroendocrinology; 2014 Oct; 48():77-86. PubMed ID: 24992721
[TBL] [Abstract][Full Text] [Related]
53. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Wu RR; Zhao JP; Zhai JG; Guo XF; Guo WB
J Clin Psychopharmacol; 2007 Aug; 27(4):374-9. PubMed ID: 17632222
[TBL] [Abstract][Full Text] [Related]
54. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
[TBL] [Abstract][Full Text] [Related]
55. Lipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatment.
Skrede S; Fernø J; Bjørndal B; Brede WR; Bohov P; Berge RK; Steen VM
PLoS One; 2012; 7(11):e50853. PubMed ID: 23226405
[TBL] [Abstract][Full Text] [Related]
56. Roman high and low avoidance rats differ in their response to chronic olanzapine treatment at the level of body weight regulation, glucose homeostasis, and cortico-mesolimbic gene expression.
Evers SS; Boersma GJ; Tamashiro KL; Scheurink AJ; van Dijk G
J Psychopharmacol; 2017 Nov; 31(11):1437-1452. PubMed ID: 28892416
[TBL] [Abstract][Full Text] [Related]
57. Metabolic and behavioral effects of chronic olanzapine treatment and cafeteria diet in rats.
Muller AP; Tort AH; Gnoatto J; Moreira JD; Vinadé ER; Perry ML; Souza DO; Lara DR; Portela LV
Behav Pharmacol; 2010 Oct; 21(7):668-75. PubMed ID: 20729714
[TBL] [Abstract][Full Text] [Related]
58. Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat.
Jassim G; Skrede S; Vázquez MJ; Wergedal H; Vik-Mo AO; Lunder N; Diéguez C; Vidal-Puig A; Berge RK; López M; Steen VM; Fernø J
Psychopharmacology (Berl); 2012 Feb; 219(3):783-94. PubMed ID: 21748251
[TBL] [Abstract][Full Text] [Related]
59. Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice.
Yoon S; Noh JS; Choi SY; Baik JH
Biochem Biophys Res Commun; 2010 Mar; 393(2):235-41. PubMed ID: 20117094
[TBL] [Abstract][Full Text] [Related]
60. Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by histamine H1 receptor agonist in female rats.
He M; Zhang Q; Deng C; Wang H; Huang XF
Endocrinology; 2014 Dec; 155(12):4895-904. PubMed ID: 25264935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
